01 2Daliresp
02 8Daliresp/Daxas
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 217
2019 Revenue in Millions : 215
Growth (%) : 1
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 227
2020 Revenue in Millions : 217
Growth (%) : 5
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 189
2021 Revenue in Millions : 227
Growth (%) : -17
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 54
2022 Revenue in Millions : 189
Growth (%) : -71
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 104
Growth (%) : New Launch
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 198
2016 Revenue in Millions : 154
Growth (%) : 29
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 189
2017 Revenue in Millions : 198
Growth (%) : -5%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 154
2015 Revenue in Millions : 104
Growth (%) : 48
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 215
2018 Revenue in Millions : 189
Growth (%) : 14
Main Therapeutic Indication : Respiratory disorders
Currency : USD
2014 Revenue in Millions :
2013 Revenue in Millions :
Growth (%) :
LOOKING FOR A SUPPLIER?